Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


MHRA approves POM to P switch of Calci-D 1000mg/1000 IU tablets

The Medicines and Healthcare products Regulatory Agency (MHRA) has concluded that Calci-D 1000mg/1000 IU tablets are “sufficiently safe to be sold as a pharmacy medicine”.

In 2015, the regulator first approved Calci-D as a prescription-only-medicine (POM) in the UK.


However, the MHRA assessed the application and decided to approve the P medicine legal status of Calci-D following a request from licence holder Consilient Health Limited to reclassify this product from POM to pharmacy (P) medicine, the watchdog said in a statement yesterday (October 7).


The MHRA approved the reclassification under the following conditions:

  • the product should be available as a 28-tablet pack

  • it should be used to correct calcium and vitamin D deficiency in the elderly

  • adults and the elderly should take one tablet a day

  • each chewable tablet contains 2500mg calcium carbonate – equivalent to 1000mg calcium – and 1000 IU – equivalent to 0.025mg – cholecalciferol (vitamin D3).


The tablets can also be used “as an adjunct to specific therapy for osteoporosis, in patients with either established vitamin D and calcium combined deficiencies or in those patients at high risk of needing such therapeutic supplements”, the MHRA said.


While there are other P medicines containing calcium and vitamin D3, Calci-D 1000mg/1000 IU tablets is the first P medicine to contain 1000 IU of vitamin D3, the MHRA added.


Assessing the application for the reclassification of the product, the MHRA said that the daily dose of vitamin D contained in the tablets “is only marginally more” than similar products currently available as P medicines.


“There is no evidence to suggest that this additional amount constitutes any additional risk,” the MHRA concluded.

Related Content


Yeovil, Winchester & Dorchester
£50-55,000 per annum

Apply Now
Latest News & Analysis
See All



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts